JP6914957B2 - 脳卒中の処置における使用のためのイマチニブ - Google Patents

脳卒中の処置における使用のためのイマチニブ Download PDF

Info

Publication number
JP6914957B2
JP6914957B2 JP2018545843A JP2018545843A JP6914957B2 JP 6914957 B2 JP6914957 B2 JP 6914957B2 JP 2018545843 A JP2018545843 A JP 2018545843A JP 2018545843 A JP2018545843 A JP 2018545843A JP 6914957 B2 JP6914957 B2 JP 6914957B2
Authority
JP
Japan
Prior art keywords
imatinib
dose
day
administered
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018545843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507165A (ja
JP2019507165A5 (enExample
Inventor
エリクソン、ウルフ
グンナー ヴァールグレン、ニルス
グンナー ヴァールグレン、ニルス
Original Assignee
ハムラ インベスト アーベー
ハムラ インベスト アーベー
ブレイン コンサルタント ニルス グンナー ヴァールグレン アーベー
ブレイン コンサルタント ニルス グンナー ヴァールグレン アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハムラ インベスト アーベー, ハムラ インベスト アーベー, ブレイン コンサルタント ニルス グンナー ヴァールグレン アーベー, ブレイン コンサルタント ニルス グンナー ヴァールグレン アーベー filed Critical ハムラ インベスト アーベー
Publication of JP2019507165A publication Critical patent/JP2019507165A/ja
Publication of JP2019507165A5 publication Critical patent/JP2019507165A5/ja
Application granted granted Critical
Publication of JP6914957B2 publication Critical patent/JP6914957B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018545843A 2016-02-29 2017-02-27 脳卒中の処置における使用のためのイマチニブ Active JP6914957B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1650260A SE539450C2 (en) 2016-02-29 2016-02-29 Imatinib for use in the treatment of stroke
SE1650260-1 2016-02-29
PCT/SE2017/050183 WO2017151043A1 (en) 2016-02-29 2017-02-27 Imatinib for use in the treatment of stroke

Publications (3)

Publication Number Publication Date
JP2019507165A JP2019507165A (ja) 2019-03-14
JP2019507165A5 JP2019507165A5 (enExample) 2020-04-09
JP6914957B2 true JP6914957B2 (ja) 2021-08-04

Family

ID=59744327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018545843A Active JP6914957B2 (ja) 2016-02-29 2017-02-27 脳卒中の処置における使用のためのイマチニブ

Country Status (17)

Country Link
US (2) US10953010B2 (enExample)
EP (1) EP3423060B1 (enExample)
JP (1) JP6914957B2 (enExample)
CN (2) CN119523986A (enExample)
AU (1) AU2017227515B2 (enExample)
DK (1) DK3423060T3 (enExample)
ES (1) ES2895432T3 (enExample)
HR (1) HRP20211621T1 (enExample)
HU (1) HUE056798T2 (enExample)
LT (1) LT3423060T (enExample)
PL (1) PL3423060T3 (enExample)
PT (1) PT3423060T (enExample)
RS (1) RS62465B1 (enExample)
RU (1) RU2739382C1 (enExample)
SE (1) SE539450C2 (enExample)
SI (1) SI3423060T1 (enExample)
WO (1) WO2017151043A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617756B2 (en) * 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
CN114306342B (zh) * 2020-09-30 2024-06-28 江苏先声药业有限公司 一种注射用伊马替尼盐的药物组合物及其制备方法
US20230279120A1 (en) * 2021-11-09 2023-09-07 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
EP4311539A1 (en) 2022-07-29 2024-01-31 Artorange Ltd. Imatinib formulation for parenteral administration
US20250000934A1 (en) 2023-06-28 2025-01-02 Pharmazz, Inc. Lyophilized sovateltide-based injectable formulation and method for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
AU2007240429A1 (en) * 2006-04-17 2007-11-01 Ludwig Institute For Cancer Research Ltd Methods and compositions for modulation of blood-neural barrier
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
KR20090061055A (ko) * 2006-10-26 2009-06-15 시코르, 인크. 결정질 및 비결정질 이매티닙 염기, 이매티닙 메실레이트 및 이들의 제조 방법
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
TR201911199T4 (tr) * 2009-03-27 2019-08-21 Moleac Pte Ltd Hücre büyümesini arttırmak için tedavi.

Also Published As

Publication number Publication date
HUE056798T2 (hu) 2022-03-28
EP3423060A4 (en) 2020-01-01
HRP20211621T1 (hr) 2022-02-04
PL3423060T3 (pl) 2022-01-10
JP2019507165A (ja) 2019-03-14
US10953010B2 (en) 2021-03-23
SE1650260A1 (en) 2017-08-30
US20190030030A1 (en) 2019-01-31
US20210236488A1 (en) 2021-08-05
AU2017227515B2 (en) 2022-03-24
PT3423060T (pt) 2021-10-20
LT3423060T (lt) 2021-11-10
CN108697711A (zh) 2018-10-23
SI3423060T1 (sl) 2021-11-30
CN119523986A (zh) 2025-02-28
WO2017151043A1 (en) 2017-09-08
RU2739382C1 (ru) 2020-12-23
DK3423060T3 (da) 2021-10-25
ES2895432T3 (es) 2022-02-21
SE539450C2 (en) 2017-09-26
AU2017227515A1 (en) 2018-08-30
EP3423060A1 (en) 2019-01-09
EP3423060B1 (en) 2021-07-21
RS62465B1 (sr) 2021-11-30

Similar Documents

Publication Publication Date Title
JP6914957B2 (ja) 脳卒中の処置における使用のためのイマチニブ
Diringer et al. Aneurysmal subarachnoid hemorrhage: strategies for preventing vasospasm in the intensive care unit
KR101987861B1 (ko) Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
US20230210880A1 (en) Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events
Du et al. Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery
US20250099466A1 (en) Milvexian for prevention and treatment of thromboembolic disorders
Yang et al. Reversal and resumption of anticoagulants in patients with anticoagulant-associated intracerebral hemorrhage
Awad et al. Dabigatran, intracranial hemorrhage, and the neurosurgeon
CN119816305A (zh) Milvexian在治疗或预防缺血性中风中的用途
JP2020511535A (ja) 中枢神経系（ｃｎｓ）がんを治療するためのプロテアソーム阻害剤の利用
JP6840197B2 (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
KR20240155278A (ko) 화농성 한선염의 치료에서 사용하기 위한 레미브루티닙
HK40073112A (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
Katayoun Vahedi Surgery for acute ischemic stroke
TW202342049A (zh) 治療患有腦損傷的患者的方法以及增加患有腦損傷的患者的擴展版格拉斯哥結局量表的值的方法
Brognaro P09. 04 Glioblastoma unique aspects dictate the ways to overcome the two causes of resistance to current therapy and find future effective treatments in the trunk-branch era
KOYAMA et al. Steroid therapy in IgA nephropathy in Japan
Estol et al. Therapy of acute stroke
Green et al. Neurovascular neurosurgery
Chalikias et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial
Appelboom¹ et al. for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
Pouratian et al. Clinical Trials in Subarachnoid Hemorrhage
WO2015054542A1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210714

R150 Certificate of patent or registration of utility model

Ref document number: 6914957

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250